載入...
Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
INTRODUCTION: Recently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement over crizotinib for advanced non-small cell lung cancer (NSCLC) patients. Therefore, the aim of this study was to e...
Na minha lista:
| 發表在: | Front Oncol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8203315/ https://ncbi.nlm.nih.gov/pubmed/34136409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.684073 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|